EndoPredict Extended Endocrine Trial (EXET)
Research payments
$1,120,819
Through program year 2022, $1,120,819 in research payments was reported against EndoPredict Extended Endocrine Trial (EXET), across 158 payments, paid by Myriad Genetic Laboratories, Inc..
- Paid by
- Myriad Genetic Laboratories, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $740,270 | 90 |
| 2021 | Research | $380,549 | 68 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Andrew Pippas Columbus, GA Named on 22 payments
- Anita Pudusseri East Syracuse, NY Named on 21 payments
- Joyce O'Shaughnessy Dallas, TX Named on 19 payments
- Adam Brufsky Pittsburgh, PA Named on 8 payments
- Timothy Larson Minneapolis, MN Named on 7 payments
- Kenneth Kernen Troy, MI Named on 6 payments
- Niyati Nathwani Lancaster, SC Named on 6 payments
- Arielle Lee Tyler, TX Named on 5 payments
- Sasha Strain Tyler, TX Named on 5 payments
- Greg Gin Long Beach, CA Named on 4 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.